Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

How Multiomics and Artificial Intelligence Are Transforming Localized NSCLC: A Deep Dive

July 28th 2025

Sandip Patel, MD, explores how AI and multiomics are transforming localized non–small cell lung cancer care.

Cellular Therapies Begin to Make Their Mark in Solid Tumors

July 24th 2025

OncLive spoke with experts working to develop cellular therapies in solid tumors to gain insights into their current standing and future in the space.

Inavolisib Plus Palbociclib/Fulvestrant Gains European Approval in PIK3CA-Mutant, HR+/HER2– Advanced Breast Cancer

July 23rd 2025

The European Commission has approved inavolisib plus palbociclib/fulvestrant in PIK3CA-mutant ER-positive, HER2-negative advanced breast cancer.

Subcutaneous Daratumumab Receives European Commission Approval in Smoldering Myeloma

July 23rd 2025

Subcutaneous daratumumab received EU approval for the treatment of patients with smoldering multiple myeloma at high risk of developing multiple myeloma.

European Commission Approves Ibrutinib in Treatment-Naive, Transplant-Eligible MCL

July 23rd 2025

Ibrutinib has received an expanded indication from the European Commission for the treatment of patients with newly diagnosed MCL eligible for transplant.

Zidesamtinib Is Set to Overcome the Limitations of Current ROS1 TKIs in ROS1+ NSCLC

July 22nd 2025

Joshua K. Sabari, MD, discusses the design of the phase 1/2 ARROS-1 study, as well as key efficacy data with zidesamtinib in ROS1 fusion–positive NSCLC.

Dr Sabari on Efficacy of Zidesamtinib in TKI-Pretreated, Advanced, ROS1+ NSCLC

July 18th 2025

Joshua K. Sabari, MD, discusses response rates observed with zidesamtinib in patients with advanced ROS1-positive non–small cell lung cancer.

Luspatercept Plus Concomitant JAK Inhibitor Therapy Misses Primary End Point in Myelofibrosis-Associated Anemia

July 18th 2025

Luspatercept plus a concomitant JAK inhibitor didn’t meet the primary end point of 12-week RBC transfusion independence in myelofibrosis-associated anemia.

FDA Grants Orphan Drug Designation to ICT01 for Acute Myeloid Leukemia

July 18th 2025

ICT01 has received orphan drug designation from the FDA for the treatment of patients with acute myeloid leukemia.

Domvanalimab Plus Zimberelimab and Chemo Set for Phase 3 Study After Showing Efficacy in Untreated Upper GI Cancers

July 16th 2025

STAR-221 will evaluate domvanalimab plus zimberelimab and chemotherapy for the first-line treatment of patients with gastric, GEJ, or esophageal adenocarcinoma.

FDA Grants Fast Track Status to ZEN-3694 Plus Abemaciclib for Unresectable or Metastatic NUT Carcinoma

July 16th 2025

ZEN-3694 has received fast track designation from the FDA for use in combination with abemaciclib for patients with previously treated NUT carcinoma.

CUE-101 Plus Pembrolizumab Yields 50% ORR in HPV+ HNSCC With Low PD-L1 Expression

July 16th 2025

In patients with HPV16-positive HNSCC, CUE-101 plus pembrolizumab generated 2 complete responses and a 12-month overall survival rate of 88%.

FDA Grants Orphan Drug Designation to SH-110 for Oral Suspension in Glioma

July 16th 2025

SH-110 received orphan drug designation from the FDA for the treatment of patients with glioma.

Sarilumab Plus Ipilimumab, Nivolumab, and Relatlimab Displays High Response Rate in Unresectable Melanoma

July 15th 2025

The combination of sarilumab, ipilimumab, nivolumab, and relatlimab displayed activity in patients with stage III or IV melanoma.

New Approaches Combat GVHD and Improve Transplantation Outcomes in Hematologic Malignancies

July 15th 2025

In an OncLive Peer Exchange filmed during EBMT, investigators discuss approaches to optimizing allo-HSCT and preventing GVHD in hematologic malignancies.

Regorafenib Plus Trifluridine/Tipiracil Shows Early Efficacy in Refractory Metastatic Colorectal Cancer

July 14th 2025

Regorafenib plus trifluridine/tipiracil was active in patients with pretreated metastatic colorectal cancer.

Dostarlimab Plus Chemo Prolongs Time to First, Second Subsequent Therapy Regardless of Age in Endometrial Cancer

July 11th 2025

After 3 years of follow-up, dostarlimab plus chemotherapy was effective and tolerable in patients aged 70 years or older with endometrial cancer.

Lisaftoclax Wins Chinese Approval in Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

July 11th 2025

The NMPA has approved lisaftoclax in adult patients with relapsed/refractory CLL/SLL.

FDA Grants Orphan Drug Designation to ADRX-0405 for Gastric Cancer

July 11th 2025

ADRX-0405 has received orphan drug designation from the FDA for the treatment of patients with gastric cancer.

Obe-Cel Is Effective Irrespective of Age in Relapsed/Refractory B-ALL

July 11th 2025

Obecabtagene autoleucel proved active and safe as treatment for patients with relapsed/refractory B-cell acute lymphoblastic leukemia regardless of age.